Jasmin Hundal, Chair of Hematology-Oncology Research Fellowship Working Group at Cleveland Clinic, shared Sarah Premji’s, Clinical Oncology Fellow at Mayo Clinic, post on LinkedIn, adding:
“Grateful to have been selected for and completed the 1-year AACR-FDA Fellowship. It has been an incredibly insightful experience to learn about cancer care, oncology advances, and drug development through the lens of regulatory science.
This fellowship reinforced how multidisciplinary progress in oncology truly is, requiring collaboration across clinicians, scientists, regulators, industry, statisticians, patient advocates, and many others working toward a common goal of improving patient outcomes.
Ending the program with a mock ODAC experience was especially valuable, offering a deeper appreciation of the complexity and responsibility involved in evaluating new cancer therapies and clinical data.
Thankful to everyone involved in creating such a thoughtful and impactful program!”
Quoting Sarah Premji’s post:
“A 9 month AACR-FDA fellowship culminating in a mock ODAC session which I was lucky enough to chair.
This experience was incredibly invaluable. Drug development and innovation is accelerating, and that’s so exciting especially for the future of oncology… but it must be done responsibly and it is incumbent upon us all to do our best to ensure that.
Our regulators are here to help in this endeavor so we collectively can improve the lives of the patients we are privileged enough to care for. There will always be differing opinions to each decision, but at the end of the day, our desire to improve the lives of patients with cancer unites us all.”
Other articles featuring Jasmin Hundal and Sarah Premji on OncoDaily.
